Plus Therapeutics launches CNSide diagnostic in Texas
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
July 31, 2025 7:30 AM EDTCNSide available for the state of Texas in August 2025
Initial commercial focus on NCI-Designated Cancer Centers and large private healthcare systems
Company will expand testing services and broaden regional availability over the next 12 months
HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc.... More
